Indian Pharma Faces Limited Threat From Trump's Tariff Plan

Indian pharmaceutical manufacturers, which dominate the global generic drug market, face limited practical risk from Trump administration proposals to impose punitive tariffs on off-patent medications, according to industry assessments. The threatened levies—beginning at 100 percent in 2028 and potentially doubling to 200 percent the following year—are designed to pressure companies into relocating production to the United States. However, several factors significantly constrain the policy's viability.

The commercial obstacles to implementation are substantial. Building pharmaceutical manufacturing capacity in the United States would require enormous capital investment and years of development. The regulatory, labor, and infrastructure costs of US-based production would substantially increase drug prices—outcomes likely to face fierce opposition from American consumers, healthcare providers, and policymakers. Generic medications have become critical to healthcare affordability in the US, and sharply higher prices would create immediate political pressure against such tariffs.

Additionally, the pharmaceutical sector commands considerable political influence in Washington. Indian generic drugmakers supply approximately 80 percent of generic medications used in the United States, creating powerful incentives for lawmakers to prevent policy measures that would disrupt supply chains or drive up drug costs for constituents. International trade obligations and pharmaceutical industry lobbying further complicate unilateral tariff implementation.

Industry observers note that while Indian pharmaceutical companies must monitor policy developments, the convergence of economic realities and political constraints suggests that such tariff threats are unlikely to be fully realized. Companies may pursue selective investments in US manufacturing while maintaining primary production in India, but wholesale relocation remains economically irrational for most producers.